33 completed, 10 terminated, 2 unknown, 1 recruiting. 47 Phase 1, 16 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 47 | Completed 33, Terminated 10, Unknown 2, Recruiting 1, Withdrawn 1 |
| Phase 2 | 16 | Completed 10, Terminated 3, Unknown 2, Withdrawn 1 |
Follow LBH589: new trials by email Literature Review of LBH589 trials Research Report on LBH589
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial Abemaciclib, Abiraterone, Afatinib - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Terminated | OHSU Knight Cancer Institute | 2 | 2020-04-01 | 2024-03-04 |
| Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat Panobinostat, Carfilzomib, Lenalidomide - Multiple Myeloma | Phase 1 / Phase 2 | Withdrawn | H. Lee Moffitt Cancer Center and Research Institute | 2017-06-01 | 2017-04-25 | |
| A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat PDR001, LCL161, Everolimus - Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma | Phase 1 | Completed | Novartis Pharmaceuticals | 298 | 2016-10-14 | 2023-01-11 |
| Trial of Panobinostat in Children With Diffuse Intrinsic Pontine Glioma LBH589 - Glioma | Phase 1 | Completed | Pediatric Brain Tumor Consortium | 53 | 2016-06-28 | 2024-04-25 |
| Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome Panobinostat, Fludarabine, Cytarabine - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 1 | Terminated | St. Jude Children's Research Hospital | 19 | 2016-05-03 | 2018-11-14 |
| Reducing the Residual Reservoir of HIV-1 Infected Cells in Patients Receiving Antiretroviral Therapy Panobinostat, Pegylated Interferon-alpha2a - HIV Infection | Phase 1 / Phase 2 | Completed | Massachusetts General Hospital | 17 | 2016-05-01 | 2024-02-28 |
| Panobinostat and Ruxolitinib In MyElofibrosis (PRIME Trial) Panobinostat, Ruxolitinib - Myelofibrosis | Phase 1 / Phase 2 | Completed | John Mascarenhas | 15 | 2013-01-01 | 2023-10-31 |
| Safety and Effect of The HDAC Inhibitor Panobinostat on HIV-1 Expression in Patients on Suppressive HAART Panobinostat - HIV Infection | Phase 1 / Phase 2 | Completed | University of Aarhus | 15 | 2012-09-01 | 2014-02-25 |
| A Phase Ib Study of Panobinostat (LBH589) in Combination With 5-Azacitidine for Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) Patients Panobinostat - Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) | Phase 1 | Completed | Novartis Pharmaceuticals | 10 | 2012-08-01 | 2020-12-19 |
| Panobinostat and Stereotactic Radiation Therapy in Treating Patients With Brain Tumors Panobinostat, Stereotactic body radiation therapy, Quality-of-life assessment - Recurrent Glioma, High-grade Meningioma | Phase 1 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 17 | 2012-05-01 | 2025-05-02 |
| Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome Panobinostat, Cytarabine, Daunorubicin - Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome | Phase 1 | Completed | University of California, San Francisco | 29 | 2012-01-01 | 2019-04-22 |
| Study of the Combination of Panobinostat & Carfilzomib in Patients With Relapsed &/or Refractory Multiple Myeloma Panobinostat, Carfilzomib, Dexamethasone - Multiple Myeloma | Phase 1 | Completed | Emory University | 32 | 2012-01-01 | 2019-01-16 |
| Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis panobinostat, ruxolitinib - Idiopathic Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis | Phase 1 | Completed | Novartis Pharmaceuticals | 61 | 2011-11-01 | 2021-06-25 |
| Panobinostat and Carfilzomib in Treating Participants With Relapsed or Refractory Multiple Myeloma Carfilzomib, Panobinostat - Non-Secretory Plasma Cell Myeloma, Plasmacytosis | Phase 1 | Completed | M.D. Anderson Cancer Center | 63 | 2011-07-28 | 2023-09-29 |
| Phase I Study of Panobinostat + Bortezomib for Relapsed and/or Refractory Mantle Cell Lymphoma (MCL) Panobinostat, Bortezomib - Mantle Cell Lymphoma | Phase 1 | Completed | Anand Jillella | 3 | 2011-04-01 | 2014-09-19 |
| A Study Of Panobinostat In Children With Refractory Hematologic Malignancies Panobinostat, Cytarabine - Lymphoblastic Leukemia, Acute, Childhood, Myelogenous Leukemia, Acute, Childhood | Phase 1 | Completed | Therapeutic Advances in Childhood Leukemia Consortium | 30 | 2011-03-01 | 2015-11-24 |
| Phase I/II Study With Oral Panobinostat Maintenance Therapy Following Allogeneic Stem Cell Transplantation in Patients With High Risk Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Panobinostat - Myelodysplastic Syndrome, Acute Myeloid Leukemia | Phase 1 / Phase 2 | Unknown | Johann Wolfgang Goethe University Hospital | 62 | 2011-01-01 | 2018-03-20 |
| Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease panobinostat - Sickle Cell Disease | Phase 1 | Recruiting | Abdullah Kutlar | 18 | 2010-11-01 | 2026-01-09 |
| Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML) Panobinostat - Acute Myeloid Leukemia (AML) | Phase 1 | Completed | Novartis Pharmaceuticals | 46 | 2010-10-01 | 2020-12-19 |
| Panobinostat and Fluorouracil Followed By Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer Who Did Not Respond to Previous Fluorouracil-Based Chemotherapy panobinostat, fluorouracil, leucovorin calcium - Recurrent Colon Cancer, Recurrent Rectal Cancer | Phase 1 | Terminated | University of Southern California | 7 | 2010-10-01 | 2015-05-27 |
Showing 20 of 47. Sign in to see all of them.
Multiple Myeloma (9) · Leukemia, Myeloid, Acute (7) · Lymphoma (6) · Hodgkin Disease (5) · Lymphoma, Non-Hodgkin (5) · Myelodysplastic Syndromes (5) · Neoplasms (5) · Prostatic Neoplasms (5) · Leukemia (4) · Primary Myelofibrosis (4) · Breast Neoplasms (3) · Glioma (3) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Recurrence (3) · Carcinoma, Non-Small-Cell Lung (2)
Novartis Pharmaceuticals (16) · Emory University (2) · M.D. Anderson Cancer Center (2) · Roswell Park Cancer Institute (2) · Abdullah Kutlar (1) · Anand Jillella (1) · City of Hope Medical Center (1) · Dana-Farber Cancer Institute (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Johann Wolfgang Goethe University Hospital (1) · John Mascarenhas (1) · Massachusetts General Hospital (1) · Mayo Clinic (1) · NYU Langone Health (1) · Novartis (1)
United States (39) · Germany (6) · Spain (4) · Australia (3) · Japan (3) · Netherlands (3) · United Kingdom (3) · Canada (2) · France (2) · Italy (2) · Sweden (2) · Switzerland (2) · Belgium (1) · Denmark (1) · Ireland (1)
Abdullah Kutlar, MD (1) · Anand Jillella, MD (1) · Anna Ferrari, MD (1) · Charalambos Andreadis, M.D. (1) · Daniel R Kuritzkes, MD (1) · F. Stephen Hodi, MD (1) · Francisco Hernandez, MD (1) · Geoffrey Uy, M.D. (1) · Gesine Bug, MD (1) · Heinz-Josef Lenz (1) · Howard A Burris, III, M.D. (1) · James R. Berenson, MD (1) · Jeffrey E. Rubnitz, MD,PhD (1) · John Mascarenhas, MD (1)
PMID 21706316, PMID 21964801, PMID 21984064, PMID 24135804, PMID 25062770, PMID 25253045, PMID 25572329, PMID 26423811, PMID 26696749, PMID 27740633, PMID 28905323, PMID 30610196, PMID 30830886, PMID 31541945, PMID 31654285, PMID 31778911, PMID 32338562, PMID 34482353, PMID 39863139
2009 (2), 2005 (1), 5UM1CA081457 (1), P30CA015083 (1), P30CA016672 (1), P30CA033572 (1)